logo

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 10590090 B1

PDFFull Text
Date of Patent:
Mar. 17, 2020

Filed:

Dec. 20, 2018

2,5-disubstituted 3-methyl pyrazines and 2,5,6-trisubstituted 3-methyl pyrazines as allosteric shp2 inhibitors

Applicant:

Revolution Medicines, Inc., Redwood City, CA (US);

Inventors:

Elena S. Koltun, Redwood City, CA (US);

Kevin Mellem, Redwood City, CA (US);

Adrian Gill, Redwood City, CA (US);

Gert Kiss, Redwood City, CA (US);

Christopher Semko, Redwood City, CA (US);

Naing Aay, Redwood City, CA (US);

Andreas Buckl, Redwood City, CA (US);

Ashutosh Jogalekar, Redwood City, CA (US);

Walter Won, Redwood City, CA (US);

Assignee:

REVOLUTION MEDICINES, INC., Redwood City, CA (US);

Attorney:

Cooley LLP

Primary Examiner:

Jeffrey H Murray

Int. Cl.
CPC ...
A61K 31/497 (2006.01); C07D 241/20 (2006.01); C07D 403/12 (2006.01); C07D 403/04 (2006.01); C07D 241/18 (2006.01); A61P 35/02 (2006.01); A61P 35/04 (2006.01); C07D 401/04 (2006.01); C07D 477/26 (2006.01); C07D 487/04 (2006.01);
U.S. Cl.
CPC ...
C07D 241/20 (2013.01); A61P 35/02 (2018.01); A61P 35/04 (2018.01); C07D 241/18 (2013.01); C07D 401/04 (2013.01); C07D 403/04 (2013.01); C07D 403/12 (2013.01); C07D 477/26 (2013.01); C07D 487/04 (2013.01);
Abstract

The present disclosure is directed to inhibitors of SHP2, such as pyrazine compounds, and their use in the treatment of disease associated with SHP2 modulation, such as Noonan Syndrome, Leopard Syndrome, juvenile myelomonocytic leukemias, neuroblastoma, melanoma, acute myeloid leukemia and cancers of the breast, lung and colon. Also disclosed are pharmaceutical compositions comprising the same.

Find Patent Forward Citations

Loading…